Loading
Loading
Research Overview
Selective MC4R agonist; directly activates hypothalamic melanocortin-4 receptors to restore appetite regulation in patients with loss-of-function mutations in the leptin/melanocortin pathway (POMC, PCSK1, LEPR, BBS). MC1R cross-activity causes universal skin hyperpigmentation.
Overview
Setmelanotide activates the melanocortin-4 receptor (MC4R) in the hypothalamus — the central appetite-regulation hub of the brain. In patients with loss-of-function mutations in genes critical to the leptin-melanocortin pathway (POMC, PCSK1, LEPR), signalling to hypothalamic MC4R is absent or severely reduced, causing extreme hyperphagia (pathological overeating) and early-onset severe obesity.
By directly activating MC4R, setmelanotide bypasses the genetic defect in the upstream signalling chain to restore appetite regulation. Clinical trials in POMC-deficient and LEPR-deficient patients demonstrated dramatic reductions in hunger and clinically meaningful weight loss — effects that are essentially specific to patients with the relevant genetic disruption, rather than reflecting general appetite suppression in all patients.
Skin hyperpigmentation is a universal side effect because MC4R and the related MC1R receptor (which controls melanin production) share the melanocortin pathway. Setmelanotide's MC1R activity produces predictable skin darkening in all patients, which is important for informed consent and patient monitoring.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, setmelanotide (imcivree) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Selective MC4R agonist; directly activates hypothalamic melanocortin-4 receptors to restore appetite regulation in patients with loss-of-function mutations in the leptin/melanocortin pathway (POMC, PCSK1, LEPR, BBS). MC1R cross-activity causes universal skin hyperpigmentation.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.